Pharmacogenetics of irinotecan

Area of Science:

• Pharmacogenetics and Oncology
• Drug Metabolism and Pharmacokinetics

Background:

• Anticancer drugs, like irinotecan, often have a narrow safety margin, leading to unpredictable severe toxicity.
• Irinotecan's complex metabolism involves multiple proteins, including human carboxylesterase (hCE1, hCE2), cytochrome P450 (CYP3A4, CYP3A5), uridino-glucuronosil transferase (UGT1A1), multi-resistance protein 2 (MRP2), and P-glycoprotein (MDR1).
• Genetic polymorphisms in these metabolizing enzymes can significantly influence irinotecan's efficacy and toxicity, with UGT1A1*28 allele linked to increased toxicity.

Purpose of the Study:

• To review recent advancements in the pharmacogenetics of irinotecan.
• To highlight the importance of individual genetic profiles in predicting irinotecan's toxicity and therapeutic effectiveness.
• To emphasize the need for personalized irinotecan therapy based on pharmacogenetic data.

Main Methods:

• Review of scientific literature on irinotecan pharmacogenetics.
• Analysis of genetic polymorphisms in key drug-metabolizing enzymes.
• Correlation of genetic variations with clinical outcomes and toxicity profiles.

Main Results:

• Multiple genes involved in irinotecan metabolism exhibit polymorphic variations.
• The UGT1A1*28 allele is specifically associated with heightened irinotecan-induced toxicity.
• Traditional clinical parameters like body-surface area show limited correlation with irinotecan treatment outcomes.

Conclusions:

• Individual genetic makeup significantly impacts irinotecan's efficacy and toxicity.
• Pharmacogenetic profiling is essential for predicting patient response to irinotecan.
• Personalized medicine approaches, guided by pharmacogenetics, are crucial for optimizing irinotecan chemotherapy.